DEA Extends Temporary Status of Benzimidazole-Opioids in Schedule I, Proposes Permanent Listings
The Drug Enforcement Administration is extending for one more year the temporary listing of three synthetic benzimidazole-opioid substances -- butonitazene, flunitazene and metodesnitazene -- in Schedule I of the Controlled Substances Act, it said in a notice released April 10.…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
The synthetic benzimidazole-opioids, first temporarily listed in 2022 (see 2204110029), will now remain listed in Schedule I until April 12, 2025. DEA also released a proposed rule to permanently list these synthetic benzimidazole-opioids in Schedule I, with comments due May 13. Substances may be temporarily listed under the CSA for three years.